In recent years, glucagon-like peptide- 1 (GLP 1) analogue injectable treatment for type 2 diabetes has been introduced to overcome some potential barriers associated with insulin medication initiation and adherence, such as weight gain and injection frequency and hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.